Immune targeted therapy for diffuse large B cell lymphoma

Yaxin Zheng, Junqi Si, Tian Yuan, Sa Ding, Chen Tian

1. INTRODUCTION

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for 30% to 40% NHL patients according to worldwide data.1 Next-generation sequencing has enabled the elucidation of the remarkable complexity of DLBCL, and some molecular targets with therapeutic potential have been identified. The continuous advancement of targeted therapy has proven that many monoclonal antibodies (MoAbs)-based drugs targeting CD20, CD38, CD22, and CD79b have significant effects on DLBCL.2

Immune checkpoint-, tumor microenvironment-, and epigenetic regulation-related therapy have also shown clinical effectiveness. In this paper, we mainly discuss the strategies and latest progress of DLBCL treatment from the perspective of MoAbs, antibody-conjugated drugs, signaling pathway inhibitors, immune checkpoint inhibitors, and epigenetic regulation aimed at improving DLBCL prognosis (Fig. 1).

2. MoAb-BASED DRUGS

The first mouse-derived MoAb muromonab-CD3 was approved by the US Food and Drug Administration (FDA). The main mechanisms of MoAb include apoptosis induction, antibody-dependent cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).

2.1. CD20 MoAbs

CD20, which is expressed on all B cell surfaces, plays an important role in the proliferation, activation, and cell cycle of human B cells. According to their distinct mechanisms, CD20 MoAbs can be classified into 2 types. Type I CD20 MoAbs, such as rituximab and ofatumumab, effectively activate the complement system and induce CDC, whereas type II agents, such as obinutuzumab, significantly initiate programmed cell death through both apoptotic and non-apoptotic mechanisms.3

Rituximab (R) is a human-murine chimeric anti-CD20 MoAb, while second-generation MoAbs are partially (-mumab) or completely (-mab) humanized. Ofatumumab (O-), which has been approved for refractory chronic lymphocytic leukemia (CLL), has also shown great potential in other B cell NHL, such as follicular lymphoma (FL) and DLBCL. A study compared the efficacy of O versus R combined with cisplatin, cytarabine, and dexamethasone (DHAP) in relapsed or refractory (R/R) DLBCL patients4 and found no difference. More clinical trials are needed to prove its efficacy.

Obinutuzumab (G) is a humanized type II anti-CD20 MoAb that has been approved by FDA for CLL in combination with chlorambucil, and has shown superior antitumor activity compared to R in xenograft models.5 A randomized phase III study demonstrated a similar prognosis for DLBCL patients treated with G-CHOP or R-CHOP.6 Another phase II multicenter study showed an objective response rate (ORR) and complete
response rate (CRR) of 75.0% and 58.0%, respectively, in CD20-positive DLBCL patients treated with G-CHOP, indicating its clinical benefits as a first-line treatment.7

2.2. CD19 MoAbs

CD19, a type I transmembrane protein belonging to the immunoglobulin (Ig) superfamily, is specifically expressed in both normal and neoplastic B cells, as well as follicular dendritic cells. Tafasitamab (MOR208), a humanized Fc-enhanced anti-CD19 MoAb, has shown preclinical and single-agent activity in R/R B cell NHL, including DLBCL,8 and is approved to use with lenalidomide. Inebilizumab (MEDI-551) is also a humanized anti-CD19 MoAb proven to be effective against CD19+ B cell lymphomas.9 A multicenter phase I study of B cell malignancies found that it was effective in R/R FL and DLBCL,10 indicting its high clinical value in B cell lymphomas expressing CD19.

2.3. CD38 MoAb

CD38 is a multifunctional type II transmembrane glycoprotein that is expressed at low levels in normal hematological cells, whereas expressed high in plasma cells and some hematological tumors, providing a novel theoretical basis for DLBCL treatment. Daratumumab (Darzalex) is a humanized CD38 MoAb with antitumor activity in B cell NHL, suggesting a potential clinical use in combination with salvage chemotherapy in DLBCL.

2.4. CD22 MoAb

CD22, commonly classified as an inhibitory receptor, is not only associated with B cell receptor (BCR) but also induces B cell responses. CD22 is highly expressed in both mature and malignant B cells, making it a target for B cell lymphoma treatment.

Epratuzumab is a humanized monoclonal IgG1 antibody that acts mainly through the induction of ADCC, CDC, and apoptosis. A phase II study reported that epratuzumab (360 mg/m²) combined with rituximab in R/R NHL patients resulted in complete response (CR).12 Another phase II trial evaluated the safety and efficacy of epratuzumab with R-CHOP in DLBCL patients, and found that the 3-year event-free survival (EFS) and overall survival (OS) were 70% and 80%, respectively.13

2.5. CD52 MoAb

CD52, a costimulatory molecule that induces T regulatory cells, is expressed in a variety of normal and malignant lymphocytes. However, its expression in DLBCL was significant heterogeneity. Alemtuzumab is a humanized anti-CD52 MoAb that recognizes the CD52 antigen expressed on both malignant and normal B lymphocytes. A study showed that of the 11 DLBCL patients who received chemotherapy combined with alemtuzumab, 62.5% achieved partial response (PR), confirming the efficacy of alezumab for B cell malignancies.14
2.6. CD40 MoAb

CD40, expressed on antigen-presenting cells such as dendritic cells, B cells, and monocytes, as well as leukemia and lymphoma cells, is a member of the tumor necrosis factor receptor (TNF) superfamily. Dacetuzumab is a humanized anti-CD40 MoAb that has antitumor effects against DLBCL with or without other drugs.

A phase I study of dacetuzumab combined with rituximab and gemcitabine in R/R DLBCL patients showed CR and PR in 6 and 8 patients, with an ORR of 47%.15 Although dacetuzumab alone showed antitumor activity in DLBCL patients, preclinical and clinical data indicated that improved antitumor activity was seen when combined with other drugs (Table 1).16

3. ANTIBODY-DRUG CONJUGATES

Antibody drug conjugates (ADCs) are MoAbs that are specific to tumor cell surface proteins and conjugated to small molecules with high cytotoxicity, which results in improved efficacy, reduced toxicity, preferable pharmacodynamics, and biodistribution.17

3.1. Anti-CD30 ADC

Brentuximab vedotin (BV), formed by an anti-CD30 MoAb and a microtubule rupture agent monomethyl auristatin E, has been approved for classical Hodgkin lymphoma.18 A phase II study evaluating the efficacy of BV monotherapy in DLBCL patients demonstrated a higher ORR,19 providing a new treatment option for refractory DLBCL patients.

3.2. Anti-CD79b ADC

Polatuzumab vedotin (Polivy™) is composed of a MoAb that recognizes CD79b and a microtubule that destroys the antimitotic agent methyl caladulin (MMAE).20 This agent is approved for R/R DLBCL in combination with bendamustine and rituximab. An open-label phase Ib/Ii study evaluated the safety and preliminary activity of polatuzumab vedotin combined with immunotherapy in previously untreated DLBCL patients21 and the results showed an ORR of 89%, including 77% CR and 12% PR.

3.3. Anti-CD22 ADC

Inotuzumab ozogamicin (INO) is a CD22-directed ADC that has been approved for R/R CD22+ precursor B cell lymphoblastic leukemia. A phase I/Ii study evaluating the safety and efficacy of INO plus rituximab in R/R B-cell NHL showed an ORR of 74% in relapsed DLBCL patients,22 demonstrating a great clinical benefit.

3.4. Anti-CD19 ADC

Loncastuximab tesirine (ADCT-402), which contains a CD19-targeting antibody, shows potent and highly targeted cytotoxicity against CD19-expressing cell lines.23 A multicenter phase I study enrolled 88 patients to evaluate the safety and clinical activity of loncastuximab tesirine in B-cell NHL.24 The results showed an ORR of 45.6%, including 26.7% CR, whereas the ORR in DLBCL was up to 42.3%.

4. BISPECIFIC T-CELL ENGAGERS

Bispecific T-cell engagers (BiTEs) are novel immunotherapy molecules to direct T-effector memory, binding to T cell-specific molecules and tumor-associated antigens.25 BiTEs are considered to be one of the most promising treatment strategies.

Blinatumomab is a bispecific CD19/CD3-directed T-cell engager that has been approved for R/R Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL). A phase I study enrolled 76 R/R NHL patients, including 14 DLBCL, to evaluate the effect of blinatumomab (60 μg m⁻²·1·day).26 In this study, the ORR of all patients was 69%, whereas that of DLBCL patients was 55%, demonstrating a promising anti-lymphoma activity of blinatumomab.

Glofitamab, a CD20/CD3 antibody, is undergoing several clinical trials. A phase Ib trial (NCT03467373) evaluating glofitamab in untreated DLBCL and a phase III trial (NCT04408638) comparing glofitamab versus rituximab combined with GemOx in R/R DLBCL are ongoing.

Mosunetuzumab (RG7828, RO7030816) is a bispecific CD20/CD3 antibody. In a phase I/Ii trial (NCT03677154), mosunetuzumab monotherapy in DLBCL received 58% ORR and 42% CR. The combination of mosunetuzumab and CHOP in a phase Ib/Ii study (NCT03677141) showed 96% ORR and 83% CR in DLBCL.

Based on the existing clinical studies, we can preliminarily believe that BiTEs have a good prospect in the clinical application of DLBCL.

5. SIGNALING PATHWAY INHIBITORS

Signaling pathways are generally considered as enzymatic reaction pathways which transmit extracellular molecular signals to intra-cells and are involved in numerous essential biological processes, such as cell proliferation, differentiation, and apoptosis.

5.1. Proteasome inhibitor

Proteasomes play an essential role in cell survival, DNA repair, degradation of abnormal proteins, and proliferation of malignant cells. Proteasome inhibitors are widely used in hematologic malignancies and have proven to significantly improve prognosis. Due to the wide application of proteasome inhibitors in therapy, we list the relevant clinical trials in Table 2.

5.1.1. First-generation proteasome inhibitors. Bortezomib is a selective 26S proteasome inhibitor with anti-proliferative and antitumor activity, and it has effects on cell proliferation, apoptosis, and angiogenesis.27 Bortezomib has been approved to treat multiple myeloma (MM) and mantle cell lymphoma (MCL). A global clinical trial recruited 49 patients to investigate whether the addition of bortezomib to doxorubicin-based chemotherapy could improve the survival of DLBCL.28 The results showed that bortezomib alone had no activity, while a higher response rate (83% vs 13%) and longer OS (10.8 vs 3.4 months) were observed in patients treated with bortezomib combined with chemotherapy. Another multicenter study also demonstrated 100% ORR with 86% CRR in DLBCL patients coadministered with bortezomib and R-CHOP, whereas the 2-year PFS and OS rates were 64% and 70%, respectively.29 However, an open-label randomized phase 3 trial showed the addition of bortezomib did not improve patients’ PFS.

5.1.2. Second-generation proteasome inhibitors. Carfizomib (CFZ), a second-generation proteasome inhibitor, has shown significant clinical activity alone and in combination with other drugs. A study found that CFZ alone or combined
| Drug                        | Type          | Disease         | Trail                                                                 | NCT        | ORR/CR               |
|---------------------------|---------------|-----------------|----------------------------------------------------------------------|------------|----------------------|
| Obinutuzumab CD20 antibody| DLBCL         | Relapsed or refractory | A dose-escalating study of obinutuzumab in patients with B-lymphocyte antigen (CD20+) malignant disease. | NCT00517350 | ORR 28% CR 4%        |
| Ublituximab CD20 antibody | DLBCL         | Relapsed or refractory | Study of humanized anti-CD20 in patients with CD20+ non-Hodgkin lymphoma. | NCT 00285428 | CR 43% CR 0%         |
| Epratuzumab CD22 antibody | DLBCL         | Relapsed or refractory | Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin lymphoma: phase I/II clinical trial results. | --         | ORR 15% CR 9%        |
| Epratuzumab with R-CHOP CD22 antibody combination | DLBCL | Monoclonal antibody therapy and combination chemotherapy in treating patients with stage II, stage III, or stage IV diffuse large B-cell lymphoma. | NCT00301821 | ORR 96% CR 74% |
| Inotuzumab ozogamicin and rituximab CD22 ADC | DLBCL | Relapsed | Study evaluating inotuzumab ozogamicin administered in combination with rituximab in subjects with non-Hodgkin lymphoma. | NCT00299404 | ORR 74% CR 50% |
| Inotuzumab ozogamicin R-CVP vs R-G-CVP CD22 ADC combination | DLBCL | Treatment of patients with diffuse large B-cell lymphoma who are not suitable for anthracycline-containing chemotherapy. | NCT01679119 | In the start |
| Polatuzumab vedotin, rituximab CD79 ADC or combination | DLBCL | A study of escalating doses of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and polatuzumab vedotin with rituximab in participants with relapsed or refractory B-cell non-Hodgkin lymphoma. | NCT01290549 | Single agent polatuzumab vedotin ORR 56% CR 16% R-pola ORR 78% CR 22% |
| Polatuzumab vedotin, obinutuzumab, polatuzumab vedotin, and rituximab CD79 ADC | DLBCL | Relapsed or refractory | A study of polatuzumab vedotin in combination with rituximab or obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, polatuzumab vedotin with rituximab in participants with relapsed or refractory B-cell non-Hodgkin lymphoma. | NCT01690898 | pina ORR 60% CR 26% R-pola ORR 54% CR 21% |
| Polatuzumab vedotin, rituximab or bendamustine, and obinutuzumab CD79 ADC | DLBCL | Relapsed or refractory | A study comparing the efficacy and safety of polatuzumab vedotin with rituximab-cyclophosphamide, doxorubicin, prednisone, versus rituximab-cyclophosphamide, doxorubicin, vinceristine, and prednisone in participants with diffuse large B-cell lymphoma. | NCT02257567 | In the start |
| Polatuzumab vedotin, R-CHP Vs R-CHOP CD79 ADC combination | DLBCL | A phase 2, multicenter, randomized, open-label study of polatuzumab in adults with relapsed or refractory DLBCL. | NCT03274492 | Recruiting |
| Inebilizumab CD19 antibody | Relapsed or refractory B-NHLs | A phase 1, dose-escalation study of inebilizumab in Japanese adult with relapsed or refractory advanced B-cell malignancies. | NCT01957579 | DLBCL ORR 50% CR 17% |
| Inebilizumab, ICE/DHAP vs rituximab, ICE/DHAP CD19 antibody | Relapsed or refractory DLBCL | A phase 2, multicenter, randomized, open-label study of inebilizumab in adults with relapsed or refractory DLBCL. | NCT01453205 | Inebilizumab (2 mg/kg), ICE/DHAP ORR 46.2% inebilizumab (4 mg/kg), ICE/DHAP ORR 43.6% rituximab, ICE/DHAP ORR 47.5% |

(continued)

www.blood-science.org 139
with BV6, a second mitochondria-derived activator of caspases mimetic, reduced cell viability, induced apoptosis, and initiated the accumulation of NOXA, which was necessary for cell death. Carfilzomib alone (NCT01336920) or combined with R-CHOP (NCT02073097), vorinostat (NCT01276717), and umbralisib (NCT02867618) in R/R lymphoma are still ongoing.

Ixazomib is an oral second-generation proteasome inhibitor approved to treat R/R MM patients. A study on the preclinical and biological effects of ixazomib indicated that ixazomib has effective antitumor activity against DLBCL, offering a more efficient therapy for R/R DLBCL. The efficacy of ixazomib in combination with rituximab (NCT02339922) or ibrutinib (NCT03323151) is currently being evaluated in indolent B-NHLs.

The combination of proteasome inhibitors and chemotherapy has shown great clinical efficacy in clinical trials, and its clinical application is worthy of further promotion.

### Table 1 (continued)

| Drug                        | Type                  | Disease          | Trail                                                                 | NCT          | ORR/CR   |
|-----------------------------|-----------------------|------------------|----------------------------------------------------------------------|--------------|----------|
| Tafasitamab                 | CD19 antibody         | Relapsed or refractory NHLs | Study of Fc-optimized anti-CD19 antibody tafasitamab to treat non-Hodgkin lymphoma. | NCT01685008  | ORR 26%  CR 6% |
| Tafasitamab                 | CD19 antibody         | Relapsed or refractory DLBCL | A study to evaluate the safety and efficacy of tafasitamab with lenalidomide in patients with relapsed or refractory DLBCL. | NCT02390085  | ORR 58%  CR 33% |
| Tafasitamab with bendamustine vs rituximab with bendamustine | CD19 antibody combination | Relapsed or refractory DLBCL | A trail to evaluate the efficacy and safety of tafasitamab with bendamustine versus rituximab with bendamustine in adult patients with relapsed or refractory DLBCL. | NCT02763319  | Recruiting |
| Coltuximab ravtansine       | CD19 ADC              | Relapsed or refractory DLBCL | Coltuximab ravtansine as single agent in relapsed or refractory DLBCL. patients. | NCT01472887  | ORR 43.9% CR 14.6% |
| Ioncastuximab tesirine      | CD19 ADC              | Relapsed or refractory DLBCL | Study to evaluate the efficacy and safety of ioncastuximab tesirine in patients with relapsed or refractory DLBCL. | NCT03589469  | In the start |
| Ioncastuximab tesirine and ibrutinib | Combination        | DLBCL             | Safety and antitumor activity study of ioncastuximab tesirine plus ibrutinib in diffuse large B-cell or mantle cell lymphoma. | NCT03684694  | Recruiting |
| Ioncastuximab tesirine and durvalumab | Combination   | DLBCL/MACL/FL     | Safety and antitumor activity study of ioncastuximab tesirine and durvalumab in diffuse large B-cell, mantle cell, or follicular lymphoma. | NCT03685344  | Recruiting |
| Dacetuzumab                 | CD40 antibody         | Relapsed DLBCL   | Study of dacetuzumab in patients with relapsed diffuse large B-cell lymphoma. | NCT00435916  | ORR 9%    CR 4% |
| Dacetuzumab, R-ICE vs placebo, R-ICE | Combination | Relapsed DLBCL   | A randomized phase 2 placebo-controlled study of R-ICE chemotherapy with and without dacetuzumab for patients with DLBCL. | NCT00529503  | Dacetuzumab, R-ICE ORR 66% CR 33% placebo, R-ICE ORR 64% CR 36% |
| Blinatumomab                | CD19/CD3 BITE         | Relapsed NHLs    | Safety study of the bispecific T-cell engager blinatumomab in patients with relapsed NHLs. | NCT00274742  | DLBCL ORR 55% CR 36%  NHLs ORR 43% CR 19% |
| Blinatumomab                | CD19/CD3 BITE         | Relapsed DLBCL   | Clinical study with blinatumomab in patients with relapsed diffuse large B-cell lymphoma. | NCT01741702  | Recruiting |
| Mosunetuzumab               | CD20/CD3 BITE         | DLBCL            | A trail of mosunetuzumab as consolidation therapy in 1/2 participants with diffuse large B-cell lymphoma following first-line immunochemotherapy and as therapy in participants with previously untreated diffuse large B-cell lymphoma who are unable to tolerate full-dose chemotherapy. | NCT03677154  | Recruiting |
| Mosunetuzumab and polatuzumab vedotin | CD20/CD3 BITE combination | B-cell NHLs      | A study to evaluate the safety and efficacy of mosunetuzumab in combination with polatuzumab vedotin in B-cell NHLs. | NCT03671018  | Recruiting |
5.2. Bruton tyrosine kinase inhibitors

Bruton tyrosine kinase (BTK) plays a crucial role in the oncogenic signaling of BCR and other receptors essential for the survival and proliferation of lymphoma cells. The BCR signaling pathway is activated in secondary lymphatic organs and drives the proliferation of malignant B cells.32 Thus, blocking this pathway provides a novel promising treatment for B cell malignancies. The BTK inhibitor-related clinical trials are listed in Table 3, aiming to provide an intuitive and clear experimental reference for the choice of the drug combination. Table 3 indicates that BTK inhibitors are less effective in treating untreated non-GCB DLBCL, and the clinical trials of its combination therapy are still ongoing.

5.2.1. Ibrutinib. Because of its high selectivity and potency, ibrutinib has become a new option for R/R NHL patients. A phase I study evaluated ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in DLBCL.

| Drug | Type | Disease | Trail | NCT | ORR/CR |
|------|------|---------|-------|-----|--------|
| Ibrutinib | BTK inhibitor | Relapsed or refractory DLBCL | Safety and efficacy study of ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma. | NCT01325701 | ABC-DLBCL 37%/16% GCB-DLBCL 5%/0% |
| Ibrutinib | BTK inhibitor | Relapsed or refractory B-NHLs | Study of the safety and tolerability of ibrutinib in patients with recurrent B-cell lymphoma. | NCT00849654 | ORR 60% CR 16% |
| Ibrutinib and rituximab | BTK inhibitor combination | Relapsed or refractory B-NHLs, CLL/SLL | A study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination of ibrutinib with rituximab in participants with hematologic malignancies. | NCT02329847 | DLBCL 36%/16% |
| Ibrutinib, lenalidomide and rituximab | BTK inhibitor combination | Untreated and unfit elderly DLBCL | Study evaluating the safety and efficacy of ibrutinib, lenalidomide, and rituximab in untreated and unfit elderly patients with DLBCL. | NCT03049062 | Recruiting |
| Ibrutinib, R-CHOP vs placebo, R-CHOP | BTK inhibitor combination | Untreated non-GCB DLBCL | A study of Bruton tyrosine kinase inhibitor, ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. | NCT01855750 | Ibrutinib, R-CHOP ORR 67.3% placebo, R-CHOP ORR 68% |
| Acalabrutinib and R-CHOP | BTK inhibitor combination | Untreated DLBCL | A combination of acalabrutinib with R-CHOP for patients with diffuse large B-cell lymphoma. | NCT03571308 | Recruiting |
| Acalabrutinib and R-ICE | BTK inhibitor combination | Relapsed or refractory DLBCL | Acalabrutinib plus R-ICE for relapsed or refractory diffuse large B-cell lymphoma. | NCT03736616 | Recruiting |
| Zanubrutinib | BTK inhibitor | Relapsed or refractory non-GCB DLBCL | Study of BTK inhibitor zanubrutinib in subjects with relapsed or refractory non-GCB type diffuse large B-cell lymphoma. | NCT03145064 | In the start |
| Vecarutinib | BTK inhibitor | B-NHLs | Safety and antitumor activity of vecarutinib in B-lymphoid cancers. | NCT03037645 | Recruiting |
Table 4
The SYK inhibitor-related clinical trials.

| Drug                  | Type        | Disease                  | Efficacy and safety of fostamatinib tablets to treat B-cell lymphoma. | NCT | ORR/CR   |
|-----------------------|-------------|--------------------------|---------------------------------------------------------------------|-----|----------|
| Fostamatinib          | SYK inhibitor | Relapsed or refractory B-cell lymphoma | Efficacy and safety of fostamatinib tablets to treat B-cell lymphoma. | NCT0446095 | ORR 22%  |
| TAK-659               | SYK inhibitor | Relapsed or refractory DLBCL | TAK-659 in participants with relapsed or refractory diffuse large B-cell lymphoma. | NCT03123393 | In the start |
| TAK-659 and R-CHOP   | SYK inhibitor combination | High-risk DLBCL | Combination chemotherapy and TAK-659 as frontline treatment in treating patients with high-risk DLBCL. | NCT03742258 | Recruiting |

Fostamatinib, an oral SYK inhibitor, is approved to treat thrombocytopenia in patients with chronic idiopathic thrombocytopenia purpura. A phase III clinical trial of fostamatinib disodium in R/R DLBCL patients determined the recommended dose to be 100 mg twice a day. In unselected R/R DLBCL patients treated with fostamatinib disodium, the ORR was 25% to 30%.

5.3.2. Entospletinib. Entospletinib (GS-9973), an oral second-generation inhibitor of SYK, has a higher selectivity and fewer adverse reactions compared to fostamatinib disodium. Entospletinib monotherapy (800 mg twice daily) was shown to have modest activity in R/R DLBCL patients in a multicenter phase II study. More clinical trials of combination treatment are needed to provide efficacy.

5.3.3. Dual SYK inhibitors. TAK-659 is an SYK/FLT3 dual inhibitor with preclinical activity in B cell malignancy models. A first-in-human study aimed at evaluating the clinical activity, safety, and tolerability of TAK-659 in R/R B cell lymphomas demonstrated an ORR of 28% with a 19% CRR in DLBCL patients. Cerdulatinib (PRT062070) is a novel, orally dual SYK/JAK inhibitor, which is confirmed the antitumor activity in DLBCL cell lines and primary DLBCL cells. A phase I study involving 16 aggressive DLBCL patients showed that cerdulatinib was well tolerated and exhibited promising antitumor activity.

5.4. Phosphoinositide 3-kinase-AKT-mechanistic target of rapamycin pathway inhibitor
The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathways are crucial to many physiological and pathological processes, including cell proliferation, angiogenesis, metabolism, differentiation, and survival. Inhibiting this pathway has been reported to be beneficial in both lymphoma cell lines and animal models.

5.4.1. PI3Kδ inhibitors. Idealisib (GS-1101) is a highly specific oral PI3Kδ inhibitor approved to treat relapsed CLL. A previous study described the mechanisms of idealisib combined with ibrutinib in non-GCB DLBCL models, and significant tumor regression was observed. Another clinical trial (NCT02457598) evaluating the efficacy of idealisib combined with ibrutinib is under the way.

Umbralisib (TGR-1202) is a novel PI3Kδ inhibitor that has been approved as a promising treatment for R/R marginal zone lymphoma patients. However, related studies of this agent in DLBCL are still rare. Parsaclisib (INCB050465) is a highly selective PI3Kδ inhibitor that demonstrated antitumor activity to improve long-term survival in R/R B-cell NHL patients in a phase I/II study. Another multicenter phase II study evaluating parsaclisib monotherapy in R/R DLBCL patients demonstrated an ORR of 25%, providing a potential new strategy for the treatment of R/R DLBCL patients.
Table 5
The PD-1 inhibitor-related clinical trials.

| Drug                  | Type         | Disease               | Trail                                                                 | NCT                  | ORR/CR            |
|-----------------------|--------------|-----------------------|----------------------------------------------------------------------|----------------------|-------------------|
| Nivolumab             | PD-1 inhibitor| Relapsed or refractory DLBCL | Study of nivolumab in patients with relapsed or refractory diffuse large B-cell lymphoma that have either failed or not eligible for autologous stem cell transplant. | NCT02038933          | 26%/18%           |
| Nivolumab             | PD-1 inhibitor| Relapsed or refractory NHL | Nivolumab in patients with relapsed or refractory hematologic malignancy; preliminary results of a phase 1 study | NCT01592370          | 41%/11%           |
| Pembrolizumab         | PD-1 inhibitor| Transformed DLBCL /relapsed or refractory CLL | Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. | NCT02323980          | 41%/11%           |
| Pembrolizumab         | PD-1 inhibitor| Relapsed or refractory GZL/extranodal DLBCL | Pembrolizumab in relapsed or refractory gray-zone lymphoma, primary central nervous lymphoma, and other extranodal diffuse large B-cell lymphoma. | NCT03255018          | Recruiting        |
| Pembrolizumab and rituximab | PD-1 inhibitor combination | Relapsed or refractory DLBCL/FL | Pembrolizumab and rituximab in treating patients with relapsed or refractory DLBCL or FL. | NCT03401853          | Recruiting        |
| Pembrolizumab and tisagenlecleucel | PD-1 inhibitor combination | Relapsed or refractory DLBCL | Study of pembrolizumab in combination with tisagenlecleucel in relapsed or refractory DLBCL patients. | NCT03630159          | Recruiting        |

5.4.2. mTOR inhibitors. Temsirolimus selectively inhibits mTOR kinase, thereby blocking the translation of cell cycle regulatory proteins and angiogenic growth factors. A phase I/II trial evaluating the safety and activity of temsirolimus added to R-DHAP as salvage therapy for R/R DLBCL patients is ongoing.47 Everolimus is an oral mTOR pathway inhibitor that has been reported to inhibit DLBCL cell growth.48 A phase I study in untreated DLBCL patients demonstrated that everolimus combined with R-CHOP was effective in both GCB and non-GCB DLBCL patients, with a CRR of 96%.49

6. IMMUNE CHECKPOINT AND IMMUNOMODULATOR

6.1. Immune checkpoint inhibitors

Instead of targeting malignant cells directly, immune checkpoint inhibitors stimulate the immune system to play an antitumor role by increasing the cytotoxicity of T cells, thereby blocking the inhibitory signals from tumor cells. Programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors are approved for many cancers, and their clinical efficacy in DLBCL is being studied.

6.1.1. PD-1/PD-L1 inhibitors. The PD-1/PD-L1 checkpoint mainly plays a negative regulatory role in T cell activation and facilitates the control of inflammatory responses and maintenance of self-tolerance. PD-L1 is the ligand of PD-1, which is constitutively expressed on macrophages and is rapidly upregulated in tumor cells. Preclinical studies have shown that inhibiting the interaction between PD-1 and PD-L1 can enhance T-cell response and mediate antitumor activity,50 providing a novel treatment strategy. To more intuitively demonstrate the clinical application research progress of PD-1 and PD-L1 inhibitors, the clinical trials of PD-1 and PD-L1 inhibitors are shown in Table 5. It can be inferred from Table 5 that single-agent PD-1 and PD-L1 inhibitors did not perform well in treating DLBCL, and combination therapies are still ongoing.

Nivolumab is an anti-PD-1 antibody that has been approved for cHL patients. A phase I study to evaluate the safety and efficacy of nivolumab enrolled 81 R/R lymphoma patients (11 DLBCL) and showed an ORR of 36% in DLBCL.51 A recent phase II study (NCT02038933) showed that nivolumab monotherapy had good safety but low ORR in DLBCL patients. Clinical trials of nivolumab combined with other immunomodulators are still in progress.

Pembrolizumab (Keytruda) is a humanized anti-PD-1 MoAb with excellent antitumor activity in R/R cHL patients.52 Another study including 30 DLBCL patients, evaluated the efficacy of pembrolizumab (200mg) with R-CHOP and showed an ORR of 90% and CRR of 77%, suggesting that this combination may be a promising treatment strategy.53 According to the current clinical trial results, the clinical benefit of anti-PD-1 antibody in DLBCL patients is not obvious.

6.1.2. CTLA-4 inhibitors. CTLA-4, also known as CD152, provides both positive and negative feedback for T cell activation when combined with its costimulatory receptor CD28. Ipilimumab is a MoAb against CTLA-4 for the first-and second-line treatment of MM. A phase I study reported that blocking CTLA-4 signals with ipilimumab at 3mg/kg had antitumor activity in R/R DLBCL patients and was well tolerated.54 However, the clinical efficacy of ipilimumab in DLBCL still requires more clinical trials evidence.

Tremelimumab, another humanized CTLA-4 MoAb, is under investigation in clinical trials for DLBCL and invasive B-cell lymphoma (NCT02549651, NCT02205333).

6.1.3. Signal-regulatory-protein α-CD47. CD47 is a widely expressed cell receptor that regulates macrophage phagocytosis, neutrophil migration, and activation of dendritic cells, T cells and
B cells by interacting with signal-regulatory-protein α (SIRPα) and other ligands.\(^5\) HuSF9-G4 is a macrophage immune checkpoint inhibitor that blocks CD47 and induces tumor cell phagocytosis. A phase Ib study involving R/R NHL patients (including 15 DLBCL) demonstrated that the ORR and CRR were 71% and 43%, respectively, in DLBCL patients who received Hu5F9-G4 combined with rituximab.\(^56\)

### 6.2. Immunomodulator

Lenalidomide is an oral immune-modulator that exerts antitumor effects through direct antineoplastic activity, inhibition of tumor cell proliferation, angiogenesis-mediated immunity, and stimulation of T and NK cell-mediated cytotoxicity. A phase I/II study reported that lenalidomide combined with R-CHOP was effective, with ORR > 90%\(^57\) and 86% CR. Now lenalidomide has been widely used in clinical practice and has achieved a good effect.

### 7. EPIGENETIC REGULATION THERAPY

Epigenetic regulation mainly involves DNA methylation, histone modification, nucleosome remodeling, and RNA-mediated targeting, which regulate many biological processes that affect the occurrence and development of B-NHL. Clinical trials of epigenetic regulation-related drugs are shown in Table 6. Table 6 indicates that DNA methyltransferase inhibitors combined with the R-CHOP regimen have a better effect on untreated DLBCL patients than chemotherapy, however, it seems to work little on R/R DLBCL. HDAC inhibitors have little effect on R/R DLBCL, and the combination therapy is still being studied.

#### 7.1. DNA methyltransferase inhibitors

DNA methyltransferase (DNMT) mediates an essential epigenetic mechanism that controls the proliferation, apoptosis, differentiation, cell cycle, and cell transformation. A previous study found that DNMT1, DNMT3a, and DNMT3b were overexpressed in 48%, 13%, and 45% DLBCL patients, respectively.\(^18\)

Azacitidine is recommended as a front-line treatment for older AML patients, and its use in other lymphomas has been evaluated.\(^59\) The results of azacitidine combined with vorinostat in R/R lymphoma patients showed that the EFR and OS rate at
15 months were 65% and 77%, respectively, among DLBCL patients.60 Another phase II/II trial (NCT01004991) of azacitidine combined with R-CHOP reported a CRR of 91.7% in untreated DLBCL patients.

Decitabine, also called AzaD, is approved for higher-risk MDS and AML patients who are not suitable for intensive therapy. A preclinical study demonstrated that decitabine combined with sorafenib induces apoptosis of DLBCL cells.61 Moreover, a phase IV trial exploring the efficacy and safety of decitabine, rituximab, with or without DHAP in R/R DLBCL (NCT03579082) is recruiting.

7.2. Enhancer of zeste homolog 2 (EZH2) inhibitors

EZH2 is a catalytic subunit of polycomb repressive complex 2 (PRC2) and found to exhibit active mutations in NHL. Tazemetostat, a first-in-class EZH2 inhibitor, has clinical activity in mutant FL and DLBCL. A phase Ib study of tazemetostat (800 mg twice daily) plus R-CHOP showed antitumor activity in newly diagnosed DLBCL patients.62

7.3. Histone deacetylase inhibitors

Histone deacetylases (HDACs) are essential for the epigenetic regulation of gene expression and control of cellular activities. HDAC inhibitors can be divided into 3 groups according to their specificity: non-selective (vorinostat, belinostat, and panobinostat), selective (romidepsin, entinostat, and ricolinostat), and multi-pharmacological. Vorinostat (Zolinza) has been approved for recurrent MM patients and AML patients who are not suitable for intensive therapy. A preclinical study demonstrated that administration of panobinostat and ibrutinib led to stronger inhibition of NF-κB and degradation of DLBCL xenografts than either agent alone did.64 A recent clinical study confirmed that administration of panobinostat as a single agent had long-lasting activity in R/R DLBCL patients.

Romidepsin, a selective HDAC inhibitor, is a promising treatment for T cell lymphoma. Preclinical studies have shown that romidepsin induces tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV+ DLBCL.65 A phase I study of romidepsin, gemcitabine, dexamethasone, and cisplatin combination therapy in DLBCL patients is ongoing (NCT01846390).

Chidamide is the first oral HDAC inhibitor approved for R/R PTCL. The latest experiment showed that the surface expression of CD20 in DLBCL cell lines was significantly increased by chidamide.66 Furthermore, co-application of chidamide with rituximab significantly enhanced cell death in vitro and in DLBCL xenograft mice.

8. CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY

T cells engineered with a chimeric antigen receptor (CAR), an emerging promising therapy, can bind to the surface antigen of target cells and induce unrestricted major histocompatibility complex (MHC)-mediated killing of tumor cells. CAR-T (CAR-T) therapy has greatly changed the treatment pattern of lymphocytic malignancies, especially DLBCL and ALL. And its efficacy in combination with other drugs is being tested in plenty of clinical trials.

8.1. Anti-CD19 CAR-T

Three anti-CD19 CAR-T cells have been approved or developed. Axicabtagene ciloleucel (KTE-C19) is an anti-CD19 CAR-T cell for R/R DLBCL with potent antitumor activity. A multicenter ZUMA-1 trial evaluating the long-term safety and activity of axicabtagene ciloleucel in refractory DLBCL, demonstrated an ORR of 83% with 58% CRR.67

Tisagenlecleucel (CTL019), which has been approved by the FDA for precursor B-cell ALL, is recently approved in Europe. An international phase II study of tisagenlecleucel in R/R DLBCL revealed an ORR of 52%, with 12% CRR and 40% PR rate (PRR).68

Lisocabtagne maraleucel (liso-cell) is a candidate drug for the treatment of R/R NHL. The ORR and CRR were 73% and 53%, respectively, in DLBCL at a dose of 100 × 10⁶.69

8.2. CD19/CD22 dual-targeted CAR-T

AUTO3, the first dual-targeted CAR-T therapy targeting both CD19 and CD22, shows great prospects in R/R DLBCL. In an ongoing phase I/II Alexander study (NCT03287817), the ORR of 75% and CRR of 63%.

Other studies targeting CD20, CD22, and CD30 CAR-T therapy are being conducted.

The results of a recent meta-analysis showed that CAR-T therapy for R/R DLBCL had an overall CRR of 46.8%70 and CRR of CD19 group was higher (49.2%) compared to CD20 group (42.2%). However, CAR-T clinical trials are rare in DLBCL, the long-term prognosis and adverse reactions such as cytokine storm still need to be validated in a large number of trials.

9. TARGETED THERAPY OF SPECIFIC ONCOGENES AND PROTEINS

9.1. B cell lymphoma 2 inhibitors

B cell lymphoma 2 (BCL2) is a crucial regulator of apoptosis. Therefore, BCL2 inhibitors are considered potentially effective agents and can be divided into various types according to the different BCL2 homology (BH) domains.

Venetoclax (ABT-199), an oral BH3 mimetic, specifically inhibits BCL2 protein and is approved as monotherapy for CLL with 17p deletion. A phase Ib study investigating venetoclax combined with R-CHOP or G-CHOP in DLBCL reported an ORR of 87.5% with CRs of 71.8%, indicating venetoclax was safe and effective in high-grade DLBCL.71 A phase 2 CAVALLI (NCT02055820) study demonstrated the combination of venetoclax and R-CHOP in DLBCL has manageable myelosuppression and the potential of improved efficacy, particularly in high-risk BCL2+ patients.

9.2. BCL6 inhibitors

BCL6 is considered as a regulator of GCB cell development and function, and it catalyzes epigenetic changes by activating co-inhibitory complexes. A preclinical study found that FX1, a specific BCL6 inhibitor, inhibited ABC-DLBCL cells both in vitro and in vivo.72

9.3. MYC inhibitors

The MYC family oncopgenes are deregulated in >50% of human cancers which associate with poor prognosis and survival.
Myc plays an important role in many carcinogenic processes through the regulation of proliferation, apoptosis, differentiation, and metabolism. MYC overexpression is associated with not only low responses but also higher CNS recurrence rates in DLBCL. The mitotic spindle-regulatory kinases Aurora A kinase (Aurora A) and Aurora B kinase are both overexpressed in MYC-associated B cells. Alisertib is an oral selective AAK inhibitor with preclinical activity against a variety of hematological malignancies. A phase I study of R/R aggressive B cell lymphoma concluded that a combination of alisertib and rituximab with or without vincristine both had clinical activities against non-GCB DLBCL.

9.4. Exportin-1 inhibitors

Exportin-1 (XPO1), also called chromosome region maintain 1, is a eukaryotic output protein associated with a poor prognosis. The XPO1 nuclear output pathway is involved in protein regulation and signal transduction of several key molecules such as p53 and epidermal growth factor. XPO1 is highly expressed in DLBCL, suggesting it could be a new treatment target.

Selinexor is a first-in-class oral XPO inhibitor that is approved for R/R MM and DLBCL in combination with dexamethasone. Recent studies showed that selinexor monotherapy induced a durable response in R/R DLBCL, with an ORR of 29% including 12% CRR and 17% PRR.

10. CONCLUSION

With the deepening understanding of the pathogenesis mechanism of DLBCL, many immune-targeted therapies have been investigated and are currently being used. Although these agents have effectively improved the prognosis of DLBCL, adverse reactions and relapses continue to occur. Despite promising trials dedicated to R/R DLBCL patients, the new options may not be easy to achieve a superiority versus the current standard treatment. Identifying therapies that can improve the CRR of first-line treatment and reduce the recurrence rate are still being conducted, and the development of precise treatment for every patient is an ongoing pursuit.

ACKNOWLEDGMENTS

CT is supported by Grant ZC20171 from Tianjin Health Science and Technology Project. TY is funded by Grant 81800148 from National Natural Science Foundation of China (NSFC).

REFERENCES

[1] Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma: a pathology 2018;50(1):74–87.
[2] Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol 2019;94(5):604–616.
[3] Meyer S, Evers M, Jansen JHM, et al. New insights in type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. Br J Haematol 2018;180(6):808–820.
[4] van Imhoff GW, Micó Milán A, Mazzaro MJ, et al. Ofatumumab versus rituximab salvage chemotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARD study. J Clin Oncol 2017;35(3):344–351.
[5] Mosnier E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115(22):4393–4402.
[6] Vitolo U, Trčňáková M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 2017;35(31):3529–3537.
[7] Sharman JP, Forero-Torres A, Costa LJ, et al. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphomas: the phase II GATHER study. Leuk Lymphoma 2019;60(4):894–903.
[8] Salles G, Duluc J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21(7):978–988.
[9] Frampton JE. Inebilizumab: first approval. Drugs 2020;80(12):1259–1264.
[10] Ohmachi K, Ogura M, Suchiro Y, et al. A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. Int J Hematol 2019;109(6):657–664.
[11] Vidal-Crespo A, Matas-Císpedes A, Rodriguez V, et al. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica 2020;105(4):1032–1041.
[12] Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 2005;23(22):5044–5051.
[13] Mckellef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma 2015;56(9):2569–2578.
[14] Yi JH, Kim SJ, Ko YH, Kim WS. Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. Leuk Lymphoma 2011;52(2):317–320.
[15] Forero-Torres A, Bartlett N, Beaven A, et al. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large-B-cell lymphoma. Leuk Lymphoma 2013;54(2):277–283.
[16] Fayad L, Annell SM, Advani R, et al. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma 2015;56(9):2569–2578.
[17] Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 2018;9(1):33–46.
[18] Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 2011;118(15):4053–4061.
[19] Yi JH, Kim SJ, Ko YH, Kim WS. Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. Leuk Lymphoma 2011;52(2):317–320.
[20] Deeks ED. Polatuzumab vedotin: first global approval. Drugs 2019;79(13):1467–1475.
[21] Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol 2019;20(7):998–1010.
[22] Fayad L, Ottiger F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphomas: results of a phase IIb study evaluating the immunomodulator inatumumab ozogamicin with rituximab. J Clin Oncol 2013;31(5):573–583.
[23] Zammarchi F, Corbett S, Adams L, et al. ADCT-402, a BDM-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 2018;131(10):1094–1105.
[24] Hamadami M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 2021;137(19):2654–2654.
[25] Huesel AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immuno Med Cell Biol 2015;39(3):290–296.
[26] Fricker LD. Proteasome inhibitor drugs. Annu Rev Pharmacol Toxicol 2020;60:457–476.
[27] Robak P, Robak T. Bortezomib for the treatment of hematologic malignancies: 15 years later. Drugs R D 2019;19(2):73–92.
Witzens-Harig M, Memmer ML, Dreyling M, Hess G. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget 2017;9(1):346–360.

Burger JA. Bruton tyrosine kinase inhibitors: present and future. Cancer J 2019;25(6):386–395.

Sauter CS, Matasar MJ, Schoder H, et al. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood 2018;131(16):1803–1808.

Dhillion S. Tirabrutinib: first approval. Drugs 2020;80(8):835–840.

Kozaki R, Vogler M, Walter HS, et al. Responses to the selective Bruton’s Tyrosine Kinase (BTK) inhibitor tirabrutinib (ONO-GS-4059) in diffuse large B-cell lymphoma cell lines. Cancers (Basel) 2018;10(4):127.

Davies A, Barrans S, Burton C, et al. ACCEPT-combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for diffuse large B-cell lymphoma (DLBCL): study protocol for a phase III open-label non-randomised clinical trial. F1000Res 2020;9:941.

Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115(13):2578–2585.

Awan FT, Thurman MJ, Patel-Donnelly D. Entoceptinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. Leuk Lymphoma 2019;60(8):1972–1977.

Lam B, Arikawa Y, Cramer J, et al. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). Bioorg Med Chem Lett 2016;26(24):5947–5950.

Gordon LI, Kaplan JB, Popat R, et al. Phase I study of TAK-659, an investigational, dual SYK/FIT3 inhibitor, in patients with B-cell lymphoma. Clin Cancer Res 2020;26(14):3546–3556.

Ma J, Xing W, Coffey G, et al. Celcudatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B-cell lymphoma. Oncotarget 2015;6(41):43881–43896.

Hamin PA, Flinn IW, Wagner-Johnston N, et al. Efficacy and safety of the dual SYK/JAK/IRAK1 inhibitors in patients with relapsed or refractory B-cell malignancies: results of a phase 1 study. Am J Hematol 2019;94(4):E80–E83.

Bertacchini J, Heidari N, Mediani L, et al. Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci 2015;72(12):2337–2347.

Yahiaou A, Meadows SA, Sorenson RA, et al. PTK787 inhibitor idelalisib in combination with BTK inhibitor ONO-4059 in diffuse large B-cell lymphoma with acquired resistance to PTK787 and BTK inhibitors. PloS One 2017;12(2):e0171221.

Forero-Torres A, Ramchandren R, Yacoub A, et al. Partalsibist, a potent and highly selective PTK787 inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood 2019;133(16):1742–1752.

Coleman M, Belada D, Casasnovas RO, et al. Phase 2 study of parsaclisib (INCB030465), a highly selective, next-generation PTK787 inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leuk Lymphoma 2021;62(2):368–376.

Witzens-Harig M, Memmer ML, Deleyling M, Hess G. A phase II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor temsirolimus added to standard therapy of rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-cell lymphoma – the STORM trial. BMC Cancer 2013;13:308.

Xu ZZ, Wang WF, Fu WB, et al. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma. Leukemia 2014;28(5):1151–1157.

Johnston PB, LaPlant B, McPhail E, et al. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCT01730185 [Alliance]): safety and efficacy results of a phase I and feasibility trial. Lancet Haematol 2016;3(5):e309–e316.

Hamashishi J, Mandai M, Matsumura N, Abiko K, Baba T, Koniishi L. PD-1PDL-1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016;21(3):462–473.

Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol 2016;34(23):2698–2704.

Chen R, Zinzani PL, Fonale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35(19):2125–2132.

Smith SD, Till BG, Shadman MS, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol 2020;189(6):1119–1126.

Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009;15(20):6446–6453.

Hayat SMG, Bianconi V, Pirro M, Jafarri MR, Hatamipour M, Sahebkar A. CD47: role in the immune system and application to cancer therapy. Cell Oncol (Dordr) 2020;43(1):19–30.

Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med 2018;379(18):1711–1721.

Vitolo U, Chiapparella A, Francescetti S, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014;15(7):730–737.

Amara K, Ziadì H, Hachana M, Soltani N, Korbi S, Trimèche M. DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. Cancer Sci 2010;101(7):1722–1730.

Schuh AC, Döhner H, Pleyer L, Seymour JF, Fenaux P, Dombret H. Azacitidine in adult patients with acute myeloid leukaemia. Curr Opin Hematol 2017;24(6):159–172.

Nieto Y, Valdez BC, Thall PF, et al. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer 2016;122(24):3837–3846.

Zhou Y, Wang X, An YH, Sun WD, Tong XM. Mechanism of sorafenib and decitabine inducing apoptosis of diffuse large B-cell lymphoma cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020;28(1):146–152.

Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 2016;6(10):a026831.

Persky DO, Li H, Rimsza LM, et al. Phase II trial of vorinostat (SAHA) in combination with rituximab–CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): a single-arm, multicentre, phase 1–2 trial. Cancer 2019;120(1):31–42.

Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):54–56.

Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396(10254):839–852.

Cao HH, Wang LL, Geng CK, et al. Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): a meta-analysis. Eur Rev Med Pharmacol Sci 2020;24(9):4921–4930.

Zelenetz AD, Sales G, Mason KD, et al. Venetoclax plus R or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood 2019;133(18):1964–1976.

Cardenas MG, Yu W, Breguel W, et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Oncol 2016;34(12):3351–3362.
[73] Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. *Blood* 2016;127(18):2182–2188.

[74] Kelly KR, Friedberg JW, Park SI, et al. Phase I study of the investigational Aurora A kinase inhibitor alisertib plus rituximab or rituximab/vincristine in relapsed/refractory aggressive B-cell lymphoma. *Clin Cancer Res* 2018;24(24):6150–6159.

[75] Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. *Lancet Haematol* 2020;7(7):e511–e522.